Metabolic dysfunction–associated steatotic liver disease (MASLD) can progress silently, allowing liver scarring to develop before symptoms appear. Assessing MASLD fibrosis risk requires more than ALT and AST: these enzymes may reflect liver-cell injury, but they do not measure liver fat, inflammation, or fibrosis, and normal levels do not rule out clinically important scarring. A practical fatty liver fibrosis test strategy begins with cardiometabolic and liver-related blood tests, followed by a FIB-4 score calculated from age, AST, ALT, and platelet count. Because FIB-4 estimates risk rather than diagnoses disease, a result that is not clearly low risk generally calls for clinician-directed secondary testing, such as vibration-controlled transient elastography (FibroScan) or the Enhanced Liver Fibrosis (ELF) blood test.
Ulta Lab Tests offers access to many of the laboratory tests that supply this information. Testing can support a more informed conversation with a qualified healthcare professional, but it cannot replace an examination, imaging, diagnosis, or individualized medical care.
MASLD means there is excess fat in the liver, called hepatic steatosis, plus at least one cardiometabolic risk factor such as excess abdominal weight, abnormal glucose, high blood pressure, high triglycerides, or low HDL cholesterol. The name replaced nonalcoholic fatty liver disease (NAFLD) in the global terminology introduced in 2023.
MASH, or metabolic dysfunction–associated steatohepatitis, is the more active form in which liver fat occurs with liver-cell injury and inflammation. MASH replaces the older term NASH. MetALD describes steatotic liver disease in a person who has metabolic dysfunction and alcohol exposure above the range used for MASLD. These labels matter because metabolic disease and alcohol can coexist; an accurate alcohol history remains part of the evaluation. The American Association for the Study of Liver Diseases (AASLD) nomenclature guide explains the current categories.
MASLD is connected to more than the liver. Insulin resistance, type 2 diabetes, abnormal cholesterol and triglycerides, hypertension, sleep apnea, chronic kidney disease, and cardiovascular disease often occur in the same pattern. That is why a useful evaluation looks beyond one liver enzyme. For a broader introduction, see Ulta Lab Tests’ guide to MASLD blood tests and metabolic risk.
Fibrosis is scar tissue produced after repeated liver injury. Early fibrosis may be reversible or may stabilize when its drivers are addressed; advanced fibrosis can progress to cirrhosis, portal hypertension, liver failure, and liver cancer. Fibrosis stage is also a stronger predictor of liver-related outcomes than the amount of fat visible on a routine scan.
The difficulty is that symptoms are a poor screening tool. A person may feel well while fibrosis develops. Fatigue or right-upper-abdominal discomfort can occur, but both are nonspecific. Jaundice, abdominal fluid, confusion, bleeding, or marked swelling tend to signal a complication that needs prompt care rather than an early warning.
ALT and AST add useful information, but their height does not equal the amount of scarring. Some people with obesity or diabetes have significant fibrosis despite values within the laboratory reference interval. The American Diabetes Association’s 2026 Standards of Care therefore recommend fibrosis-risk assessment in relevant adults with type 2 diabetes or prediabetes and cardiometabolic risk, including those with normal liver enzymes.
Risk assessment is especially relevant when one or more of the following are present. These findings do not prove MASLD or fibrosis; they identify situations in which a clinician may reasonably look further.
| Finding | What it may suggest | Tests or follow-up that may help |
|---|---|---|
| Type 2 diabetes or prediabetes with another metabolic risk | A higher-risk setting for MASH and fibrosis, even with normal ALT | CBC, liver chemistry, A1C, lipids, FIB-4, then elastography or ELF when indicated |
| Obesity, increased waist circumference, high triglycerides, low HDL, or hypertension | Cardiometabolic drivers commonly associated with liver fat | A1C or glucose, lipid panel, CMP, CBC with platelets, blood-pressure assessment |
| Fatty liver reported on ultrasound, CT, or MRI | Steatosis is present, but imaging alone does not establish MASH or fibrosis stage | History, laboratory evaluation, FIB-4, and secondary fibrosis assessment when appropriate |
| Persistently elevated ALT or AST | Ongoing liver or muscle injury; MASLD is one of several possibilities | Repeat in context; review alcohol, medicines, supplements, viral hepatitis, iron, autoimmune, and muscle factors |
| High ferritin | Metabolic inflammation, liver injury, infection, alcohol effects, or iron overload | Serum iron, TIBC or transferrin, and transferrin saturation rather than ferritin alone |
| Platelets trending down while AST or FIB-4 rises | Possible advancing fibrosis or portal hypertension, although many other causes exist | Repeat CBC, liver chemistry, medication review, imaging, and timely clinical evaluation |
| Sleep apnea, polycystic ovary syndrome, or several metabolic risks | A broader insulin-resistance pattern that may increase MASLD probability | Individualized metabolic and fibrosis-risk assessment |
A practical baseline often includes a CBC with platelets; a comprehensive metabolic panel containing AST, ALT, alkaline phosphatase, bilirubin, albumin, glucose, creatinine, and electrolytes; A1C; a lipid panel; and selected kidney and iron markers. GGT may help when alcohol exposure, a medication effect, or a cholestatic pattern is possible. This baseline does three jobs: it supplies FIB-4 inputs, shows metabolic drivers, and identifies clues that may point away from uncomplicated MASLD.
One unexpected result is rarely the endpoint. Acute illness, dehydration, strenuous exercise, recent alcohol exposure, and medication or supplement effects can change values. Persistently abnormal aminotransferases—often considered persistent at about six months—deserve clinician-directed investigation rather than indefinite repetition without a cause.
The Fibrosis-4 index is calculated as (age × AST) ÷ (platelet count × √ALT), using age in years, AST and ALT in U/L, and platelets in 109/L. Its value is mainly its ability to sort people into broad probability groups.
| Age group | Lower probability | Indeterminate | Higher probability |
|---|---|---|---|
| 35–64 years | Below 1.3 | 1.3–2.67 | Above 2.67 |
| 65 years or older | Below 2.0 | 2.0–2.67 | Above 2.67 |
| Younger than 35 | FIB-4 is less accurate; do not rely on standard thresholds alone when metabolic risk or liver abnormalities are substantial. | ||
These are triage thresholds, not diagnostic boundaries. In suitable primary-care populations, a low FIB-4 has a strong negative predictive value for advanced fibrosis, but it does not mean “no fatty liver” or “healthy liver.” FIB-4 can also miss at-risk MASH, particularly in people with obesity or type 2 diabetes. A high score does not prove cirrhosis.
Do not rely on FIB-4 during acute illness, a short-lived aminotransferase spike, or a temporary platelet disturbance. Age can inflate the score in older adults; muscle injury can raise AST; and unrelated platelet disorders can change the denominator. The AASLD noninvasive assessment pathway and the 2026 American Gastroenterological Association (AGA) pathway update support this staged interpretation.
MASLD is common, but it should not become a catch-all explanation for every abnormal liver test. The next tests depend on age, history, alcohol exposure, medicines, supplements, family history, and the biochemical pattern. A clinician may consider hepatitis B and C testing, iron studies, autoimmune markers such as ANA, smooth-muscle antibody and IgG, alpha-1 antitrypsin testing, ceruloplasmin in selected younger people, celiac testing, or imaging of the gallbladder and bile ducts.
This is targeted testing—not a recommendation that everyone order every marker. An AST rise after intense exercise may call for creatine kinase; an isolated alkaline phosphatase pattern may require a different pathway; and a high ferritin should be interpreted with transferrin saturation before assuming iron overload.
If FIB-4 is indeterminate or high, or if clinical concern remains despite a low result, common next steps are vibration-controlled transient elastography (VCTE, often called FibroScan) or the Enhanced Liver Fibrosis (ELF) blood test. Magnetic resonance elastography is used in selected cases. Liver biopsy is not required for everyone, but it may clarify MASH, fibrosis stage, or competing diagnoses when noninvasive findings disagree or a treatment decision requires greater certainty.
| Tool | What it estimates | Practical interpretation | Important limits |
|---|---|---|---|
| VCTE/FibroScan | Liver stiffness; many devices also estimate steatosis | In the 2026 AGA pathway, less than 8 kPa supports lower risk; 8 kPa or more prompts hepatology evaluation or further stratification. | Inflammation, congestion, recent food intake, obesity, and measurement quality can affect stiffness. |
| ELF blood test | A composite of three markers related to matrix turnover and fibrosis | Useful where elastography is unavailable; the 2026 AGA pathway uses 9.2 as a referral threshold. | Cutoffs vary by pathway and purpose; use the laboratory report and clinical context. |
| Magnetic resonance elastography | Liver stiffness across a larger portion of the liver | Often reserved for selected or discordant cases | Availability, cost, technical factors, and clinical context matter. |
| Liver biopsy | Steatosis, inflammation, liver-cell injury, and fibrosis in sampled tissue | Can confirm MASH and stage fibrosis when greater certainty is necessary | Invasive, subject to sampling variation, and not a first test for most people. |
Routine ultrasound can show liver fat, but it may miss mild steatosis and cannot reliably determine whether MASH or significant fibrosis is present. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) diagnosis guide explains the different roles of blood tests, imaging, elastography, and biopsy.
Follow-up should return to the original abnormalities and the metabolic drivers. Useful trends can include ALT, AST, GGT, bilirubin, albumin, platelets, FIB-4, A1C, glucose, triglycerides, LDL cholesterol, ApoB, creatinine, urine albumin, weight, waist circumference, and—when appropriate—ELF or elastography. Improvement in ALT alone does not prove fibrosis has improved.
No single panel answers every MASLD question. The most useful combination depends on whether the goal is initial risk assessment, investigation of an atypical pattern, or monitoring. Candidate Ulta product links in this draft still require direct editorial confirmation before publication.
| Test | What it measures | Why it may matter | How a pattern may be interpreted | Key limitation |
|---|---|---|---|---|
| FIB-4 Index Liver Health Evaluation (Self Calculation) | Combines age, AST, ALT, and platelets | First-line triage for advanced-fibrosis probability | Low, indeterminate, or higher-risk categories guide the next step | Not diagnostic; age, acute illness, muscle injury, and platelet disorders can distort it |
| Comprehensive Metabolic Panel Test - CMP | Includes AST, ALT, alkaline phosphatase, bilirubin, albumin, glucose, creatinine, and electrolytes | Shows liver chemistry, synthetic clues, glucose, and kidney context | Patterns matter more than one value; bilirubin or albumin changes may be important in advanced disease | Does not measure liver fat, inflammation, or fibrosis directly |
| Complete Blood Count with Differential and Platelets | Blood-cell counts, including platelets | Provides the platelet input for FIB-4 and may reveal anemia or infection | A falling platelet trend can accompany advanced fibrosis but has many other causes | A single low count does not establish portal hypertension or liver disease |
| GGT Test | Gamma-glutamyl transferase activity | Adds context to liver and bile-duct patterns and may rise with alcohol or medication effects | Elevation can support a hepatic source of alkaline phosphatase | Nonspecific and cannot stage fibrosis |
| Hemoglobin A1c (HbA1c) | Average glucose exposure over roughly two to three months | Identifies dysglycemia, a major driver of MASLD progression risk | Higher values may indicate prediabetes or diabetes when interpreted by accepted criteria | Anemia, altered red-cell turnover, kidney disease, and hemoglobin variants can affect it |
| Lipid Panel Test | Total cholesterol, HDL, LDL, and triglycerides | Characterizes dyslipidemia and cardiovascular risk that often accompany MASLD | High triglycerides or low HDL may support a metabolic-risk pattern | Does not diagnose liver disease; fasting requirements depend on the test and clinical goal |
| Apolipoprotein B Test | The number of atherogenic lipoprotein particles | May refine cardiovascular risk when triglycerides, diabetes, or discordant lipids are present | A higher result can indicate more atherogenic particles | Not a liver-fibrosis marker and not necessary for every person |
| Ferritin Test | An iron-storage protein that also rises with inflammation | May be elevated in metabolic liver disease or true iron overload | Interpret with iron, TIBC or transferrin, and transferrin saturation | High ferritin alone does not diagnose hemochromatosis or MASLD |
| Iron and Total Iron Binding Capacity Test | Circulating iron and iron-binding capacity | Helps calculate transferrin saturation and investigate iron overload or deficiency | High transferrin saturation may warrant further evaluation in the right context | Results vary with timing, supplements, inflammation, and recent intake |
| Albumin Random Urine with Creatinine | Urine albumin-to-creatinine ratio | Checks for kidney injury in the same diabetes and hypertension risk network | Persistent elevation may indicate kidney damage | Exercise, infection, menstruation, fever, and temporary factors can raise it |
| Enhanced Liver Fibrosis (ELF) Score | Three serum markers associated with extracellular-matrix turnover | Provides a second-tier estimate of fibrosis risk | Higher results increase concern and may support referral or further evaluation | Not a stand-alone diagnosis; cutoffs depend on pathway and context |
| TSH and Free T4 Test | Thyroid regulation and circulating free thyroxine | May clarify fatigue, weight, or lipid patterns when thyroid disease is plausible | Abnormal values may identify a separate endocrine contributor | Does not diagnose MASLD and is best used when the history or pattern supports it |
| Creatine Kinase Total Test | An enzyme released from skeletal muscle | Can help interpret AST elevation after strenuous exercise or muscle injury | High CK supports muscle injury as a contributor to the pattern | Nonspecific and not a routine MASLD test |
Lab testing can identify liver-cell injury, supply FIB-4 inputs, show metabolic drivers, reveal kidney and cardiovascular risk, and provide clues to alternative causes. Repeated results can show whether a pattern is stable, improving, or worsening.
Lab testing cannot show the exact amount of liver fat, prove MASH, stage fibrosis with certainty, or replace imaging and clinical assessment. A normal result does not always eliminate concern, and an abnormal result does not automatically mean disease. Reference intervals describe the distribution expected for a laboratory’s method; clinical decision thresholds such as FIB-4 cutoffs answer a different question.
Results vary with age, sex, pregnancy, hydration, fasting status, recent illness, exercise, alcohol, medicines, supplements, and laboratory method. Compare trends only when the inputs are clinically comparable, and discuss unexpected findings with a healthcare professional.
There is no single interval for everyone. Current pathways commonly reassess FIB-4 every one to two years in people with type 2 diabetes, prediabetes, or multiple metabolic risks. People without diabetes and with fewer risks may be reassessed every two to three years. A clinician may repeat testing sooner after a new abnormality, a medication or supplement change, acute illness, substantial metabolic change, or a treatment decision.
Low risk is not “no risk.” Conversely, repeating a high FIB-4 without arranging secondary assessment can delay the more useful next step. The purpose of retesting is to answer a defined question: Did a temporary abnormality resolve? Is metabolic risk improving? Is fibrosis probability stable? Does the person now need elastography or specialist evaluation?
Managing MASLD generally means addressing weight and waist circumference, glucose, triglycerides and cholesterol, blood pressure, sleep apnea, physical activity, dietary quality, and alcohol exposure. The NIDDK’s MASLD treatment overview emphasizes gradual, sustainable weight management and physical activity. Starting, stopping, or changing a medicine requires an individualized clinical plan.
As of August 2026, the U.S. Food and Drug Administration has granted accelerated approval to resmetirom (Rezdiffra) and semaglutide marketed as Wegovy for selected adults with noncirrhotic MASH and moderate-to-advanced F2–F3 fibrosis. These are clinician-prescribed treatments used with diet and physical activity; a high ALT, fatty liver on ultrasound, or FIB-4 result alone does not establish eligibility. See the FDA announcements for resmetirom and Wegovy for MASH.
MASLD also warrants attention to connected organs. Ulta’s educational resources on the liver health and metabolic lab dashboard, kidney health in the cardiometabolic pattern, and cardiovascular health blood tests can help readers see those connections.
Do not wait for routine self-directed testing if you develop yellow skin or eyes; new abdominal swelling; vomiting blood or black stools; confusion, unusual sleepiness, or a personality change; marked leg swelling; easy bleeding or widespread bruising; severe right-upper-abdominal pain with fever or vomiting; or major liver-test abnormalities after starting a medicine or supplement. These findings may reflect advanced liver disease, bleeding, bile-duct obstruction, acute hepatitis, medication injury, or another urgent condition.
Where available, patients can review and order many relevant laboratory tests online through Ulta Lab Tests and access results through a secure online portal. Direct access can make it easier to assemble current results and follow comparable trends. It does not replace a clinician’s assessment, especially when FIB-4 is not clearly low, results conflict, symptoms are present, or elastography and treatment decisions are being considered.
No. ALT and AST can be normal in people with MASLD, MASH, or significant fibrosis, particularly in higher-risk settings such as obesity and type 2 diabetes. Enzymes reflect injury at the time of testing; they do not directly measure fat or scar tissue. Risk factors, platelets, FIB-4, and sometimes elastography or ELF provide additional information.
Initial testing commonly includes AST, ALT, platelets, bilirubin, albumin, alkaline phosphatase, glucose or A1C, and lipids. Age, AST, ALT, and platelets produce FIB-4. Depending on the pattern, kidney markers, iron studies, viral hepatitis tests, autoimmune markers, thyroid testing, or CK may be useful. ELF is a second-tier fibrosis blood test.
No. FIB-4 estimates the probability of advanced fibrosis and helps decide who may need another test. A low result reduces probability but cannot exclude all fibrosis or MASH. An elevated result can be caused by age, temporary AST elevation, or low platelets from another condition. Elastography, specialist assessment, and occasionally biopsy provide greater clarification.
For many adults ages 35–64, less than 1.3 is lower risk, 1.3–2.67 is indeterminate, and above 2.67 is higher risk. In adults 65 or older, less than 2.0 is often used as the lower-risk threshold. These are pathway cutoffs, not diagnoses; people younger than 35 and those with acute illness need special caution.
A routine ultrasound may detect liver fat, but it may miss mild steatosis and cannot reliably stage fibrosis or identify MASH. Elastography is designed to estimate liver stiffness and is more useful for fibrosis risk. Magnetic resonance methods and, in selected cases, biopsy may be considered when results are unclear or greater certainty is required.
People with type 2 diabetes, prediabetes plus cardiometabolic risk, obesity, multiple metabolic risks, fatty liver on imaging, persistent aminotransferase elevation, or signs of chronic liver disease should discuss assessment with a clinician. Individual risk, age, alcohol exposure, medicines, family history, and competing liver conditions determine the appropriate pathway.
It depends on the tests ordered. FIB-4 inputs do not inherently require fasting, but glucose, triglyceride, or iron testing may have specific timing or fasting instructions. Follow the directions for each test. Tell the interpreting clinician about recent meals, alcohol, exercise, illness, medicines, and supplements because these factors can affect results.
Many current pathways use one- to two-year reassessment for people with diabetes, prediabetes, or multiple metabolic risks, and two to three years for some lower-risk people. Earlier testing may be appropriate after an unexpected result or a meaningful clinical change. An indeterminate or high result usually needs secondary assessment rather than routine repetition alone.
Many relevant blood tests can be ordered directly online where available. However, ordering access does not make interpretation simple. A clinician should integrate the results with symptoms, physical findings, alcohol and medication history, imaging, and other conditions. Elastography, biopsy decisions, prescription treatment, and urgent abnormalities require professional evaluation.
MASLD describes liver steatosis in a person with at least one cardiometabolic risk factor. MASH is the inflammatory, liver-cell-injury form of the disease and may occur with or without significant fibrosis. Routine liver enzymes and ultrasound cannot reliably prove MASH. Noninvasive risk tests guide evaluation, while biopsy may be used when confirmation would change care.
Finding MASLD fibrosis risk before symptoms appear requires more than checking whether ALT and AST are “normal.” Start with the metabolic and liver pattern, calculate FIB-4 from a clinically appropriate blood draw, investigate competing causes when the pattern calls for it, and use ELF, elastography, or specialist assessment when risk is not clearly low. Ulta Lab Tests can provide access to many of the blood tests discussed here, but each result should become part of an informed conversation with a qualified healthcare professional.
Disclosure: Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.
These tests should be selected according to the history and laboratory pattern rather than ordered routinely for everyone.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
